M Holdings Securities Inc. bought a new position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Rating) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,750 shares of the specialty pharmaceutical company’s stock, valued at approximately $30,000. M Holdings Securities Inc. owned about 0.07% of Cumberland Pharmaceuticals as of its most recent SEC filing.
Separately, Acadian Asset Management LLC grew its holdings in shares of Cumberland Pharmaceuticals by 27.8% during the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after buying an additional 40,949 shares in the last quarter. 18.48% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Sunday. They set a “hold” rating for the company.
Cumberland Pharmaceuticals Trading Down 1.1 %
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- Get a free copy of the StockNews.com research report on Cumberland Pharmaceuticals (CPIX)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.